Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[New antidepressive drugs].

B Woggon1

  • 1Psychiatrische Universitätsklinik, Zürich.

Praxis
|April 25, 2000
PubMed
Summary

Recent antidepressant development focuses on selective serotonin reuptake inhibitors (SSRI), SNRIs, and others, aiming for specific biochemical effects and fewer side effects. Further advancements promise new classes to combat therapy-resistant depression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction: Non-Response to Antidepressants: Risk Factors and Therapeutic Possibilities.

Pharmacopsychiatry·2026
Same author

Psychostimulants in the therapy of treatment-resistant depression Review of the literature and findings from a retrospective study in 65 depressed patients.

Dialogues in clinical neuroscience·2011
Same author

[Depression is by far the most frequent psychiatric disorder].

Therapeutische Umschau. Revue therapeutique·2000
Same author

[Pharmacologic treatment of depression].

Therapeutische Umschau. Revue therapeutique·2000
Same author

[New psychotropic drugs--is only the price new?].

Praxis·1999
Same author

Steady state concentrations of the enantiomers of mianserin and desmethylmianserin in poor and in homozygous and heterozygous extensive metabolizers of debrisoquine.

Therapeutic drug monitoring·1998

Area of Science:

  • Pharmacology
  • Neuroscience
  • Medicinal Chemistry

Context:

  • The evolution of antidepressant pharmacotherapy has introduced novel drug classes.
  • Key advancements include selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), serotonin antagonists, reversible selective inhibitors of monoamine oxidase A (RIMAs), and St. John's Wort.

Purpose:

  • To explore the development of novel antidepressant pharmacotherapies.
  • To highlight the driving principles behind new antidepressant drug discovery: enhanced biochemical specificity and reduced adverse effects.
  • To anticipate future trends in antidepressant drug development.

Summary:

  • Five major classes of antidepressants have emerged recently, including SSRIs, SNRIs, serotonin antagonists, RIMAs, and St. John's Wort.
  • These newer agents were developed with the primary goals of achieving more targeted biochemical actions and minimizing side effects compared to older treatments.
  • The trajectory of antidepressant research indicates the imminent arrival of at least three additional substance groups with distinct biochemical mechanisms.

Impact:

  • The expanding array of antidepressant options is crucial for addressing treatment-resistant depression.
  • Future pharmacological interventions are expected to offer improved efficacy and tolerability profiles.
  • This ongoing innovation in psychopharmacology holds significant promise for patients with complex depressive disorders.

Related Experiment Videos